Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
FDA Makes Moves To Modernize Drug Development, Clinical Trial Paradigm
On April 28, 2026, the Food and Drug Administration (FDA) unveiled two major announcements as part of its initiative to “advance the implementation of real-time clinical trials.” In conjunction with a request for information (RFI) for a proposed pilot program, the agency announced the successful initiation of two proof-of-concept real-time clinical trials (RTCTs). Taken together, the agency’s stated goal is to enable continuous trials and reduce the “hiatuses” between the phases of clinical development, ultimately improving the drug development process.
United States Healthcare
AG
Akin Gump Strauss Hauer & Feld LLP
Podcast
FDA Turns Up The Heat On GLP 1 Dupes Sold ​“For Research Use Only,” Finds Intended Use Suggests Otherwise (Podcast)
The FDA has launched a major enforcement initiative against companies marketing unapproved GLP-1 weight loss drug alternatives as "research use only" or "not for human consumption" while simultaneously providing dosing instructions and testimonials. This episode examines how regulators are looking beyond legal disclaimers to focus on actual marketing practices and intended use, signaling heightened scrutiny of the booming market for compounded and unapproved GLP-1 products.
United States Healthcare
KD
Kelley Drye & Warren LLP
See more

Webinars

See More

Highlighted Content

Healthcare

Article
What FDA’s Latest Peptide Action Really Means For Compounding Pharmacies
FDA's recent procedural action on certain peptide nominations has sparked confusion in the compounding pharmacy space, with some interpreting it as broad authorization for peptide compounding. However, this development represents a limited procedural step rather than final regulatory clearance, and pharmacies that rush to expand peptide offerings based on incomplete information may face significant regulatory, operational, and business risks. The distinction between interim categorization changes and defini
United States Healthcare
BI
Buchanan Ingersoll & Rooney PC
See more

Food and Drugs Law

Article
FDA Makes Moves To Modernize Drug Development, Clinical Trial Paradigm
On April 28, 2026, the Food and Drug Administration (FDA) unveiled two major announcements as part of its initiative to “advance the implementation of real-time clinical trials.” In conjunction with a request for information (RFI) for a proposed pilot program, the agency announced the successful initiation of two proof-of-concept real-time clinical trials (RTCTs). Taken together, the agency’s stated goal is to enable continuous trials and reduce the “hiatuses” between the phases of clinical development, ultimately improving the drug development process.
United States Healthcare
AG
Akin Gump Strauss Hauer & Feld LLP
Article
What FDA’s Latest Peptide Action Really Means For Compounding Pharmacies
FDA's recent procedural action on certain peptide nominations has sparked confusion in the compounding pharmacy space, with some interpreting it as broad authorization for peptide compounding. However, this development represents a limited procedural step rather than final regulatory clearance, and pharmacies that rush to expand peptide offerings based on incomplete information may face significant regulatory, operational, and business risks. The distinction between interim categorization changes and defini
United States Healthcare
BI
Buchanan Ingersoll & Rooney PC
See more

Life Sciences, Biotechnology & Nanotechnology

Article
FDA Makes Moves To Modernize Drug Development, Clinical Trial Paradigm
On April 28, 2026, the Food and Drug Administration (FDA) unveiled two major announcements as part of its initiative to “advance the implementation of real-time clinical trials.” In conjunction with a request for information (RFI) for a proposed pilot program, the agency announced the successful initiation of two proof-of-concept real-time clinical trials (RTCTs). Taken together, the agency’s stated goal is to enable continuous trials and reduce the “hiatuses” between the phases of clinical development, ultimately improving the drug development process.
United States Healthcare
AG
Akin Gump Strauss Hauer & Feld LLP
Podcast
FDA Turns Up The Heat On GLP 1 Dupes Sold ​“For Research Use Only,” Finds Intended Use Suggests Otherwise (Podcast)
The FDA has launched a major enforcement initiative against companies marketing unapproved GLP-1 weight loss drug alternatives as "research use only" or "not for human consumption" while simultaneously providing dosing instructions and testimonials. This episode examines how regulators are looking beyond legal disclaimers to focus on actual marketing practices and intended use, signaling heightened scrutiny of the booming market for compounded and unapproved GLP-1 products.
United States Healthcare
KD
Kelley Drye & Warren LLP
See more

Latest Videos

See more

Upcoming Events